Clinical Trial Update: An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 trial updating effectiveness and safety of inhaled JNJ 49095397 (RV568) in moderate-to-severe COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• JNJ 49095397 (RV568) (JNJ 49095397 (RV568))

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED